Soleil Boughton Sells 54,153 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 54,153 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $29.90, for a total transaction of $1,619,174.70. Following the completion of the sale, the insider now owns 165,650 shares in the company, valued at $4,952,935. This represents a 24.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total transaction of $70,055.70.
• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.16, for a total value of $54,171.24.

Hims & Hers Health Stock Down 0.0 %

NYSE HIMS opened at $30.89 on Friday. The firm has a market cap of $6.75 billion, a price-to-earnings ratio of 70.20 and a beta of 1.31. The business has a 50-day moving average price of $28.22 and a 200-day moving average price of $22.17. Hims & Hers Health, Inc. has a twelve month low of $8.51 and a twelve month high of $35.02.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.04) earnings per share. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Ratings Changes

HIMS has been the topic of a number of research reports. BTIG Research initiated coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target on the stock. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Citigroup cut Hims & Hers Health from a “neutral” rating to a “sell” rating and raised their target price for the stock from $24.00 to $25.00 in a report on Friday, January 10th. Finally, Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their target price for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $25.13.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently made changes to their positions in HIMS. Quest Partners LLC lifted its position in shares of Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after buying an additional 807 shares in the last quarter. Stonekeep Investments LLC lifted its position in shares of Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after buying an additional 882 shares in the last quarter. CWM LLC lifted its position in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares in the last quarter. Cadent Capital Advisors LLC lifted its position in shares of Hims & Hers Health by 1.5% in the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock worth $1,745,000 after buying an additional 1,060 shares in the last quarter. Finally, Raleigh Capital Management Inc. lifted its position in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.